EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study

Yuki Hanai, Kazuaki Matsumoto, Aiju Endo, Kazumi Hanawa, Hideki Hashi iD, Taito Miyazaki, Tetsuo Yamaguchi, Sohei Harada iD, Takuya Yokoo, Shusuke Uekusa, Daiki Asakawa, Yoshiaki Yokoyama und 7 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae442 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Yuki Hanai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Staphylococcal Infections, Staphylococcus, Vancomycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although vancomycin is commonly used to treat methicillin-resistant coagulase-negative staphylococci (MRCoNS) infections, there are no clear guidelines for the optimal 24 h AUC24/MIC ratio. This study aimed to determine the target AUC24/MIC ratio associated with vancomycin-treated MRCoNS infection outcomes.

Methods

This multicentre retrospective cohort study included adult patients who received vancomycin for ≥5 days for bloodstream infections caused by MRCoNS between January 2018 and December 2023. Primary outcome was treatment success, defined as a composite of survival beyond 30 days, clinical success and microbiological eradication. Secondary outcomes included 30-day mortality, clinical success, microbiological eradication and nephrotoxicity. Receiver operating characteristic (ROC) curve analysis was used to identify the AUC24/MIC cut-off for treatment success. Multivariate regression analysis was used to determine the association between AUC24/MIC and outcomes.

Results

This study included 147 patients. ROC analysis identified a target AUC24/MIC ≥373 for treatment success. The overall treatment success rate (70.1%) was significantly higher in the above-average AUC24/MIC cut-off group (83.1%) than that in the below AUC24/MIC cut-off group (57.9%). Multivariate analysis confirmed that AUC24/MIC ≥373 was an independent predictor (adjusted OR = 10.227; 95% CI = 3.585–29.171). The 30-day mortality and microbiological eradication rates differed significantly between the below- and above-cut-off groups, whereas nephrotoxicity rates were comparable among the groups.

Conclusions

In treating MRCoNS infections, vancomycin AUC24/MIC ratio ≥373 was independently associated with favourable treatment outcomes. However, further prospective studies are required to confirm this target owing to the retrospective nature of this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsStaphylococcal InfectionsStaphylococcusVancomycinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCoagulaseMethicillin ResistanceMicrobial Sensitivity TestsRetrospective StudiesROC CurveTreatment Outcome

Substanzen

Anti-Bacterial AgentsCoagulaseVancomycin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
  • Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Department of Pharmacy, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
  • Department of Pharmacy, Kameda Medical Center, Chiba, Japan.
  • Department of Pharmacy, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
  • Department of General Medicine and Emergency Care (Infectious Diseases), Toho University Omori Medical Center, Tokyo, Japan.

ORCID-Profile: Hideki Hashi, Sohei Harada, Yuki Enoki, Kazuaki Taguchi

Zitieren

APA

Hanai, Y., Matsumoto, K., Endo, A., Hanawa, K., Hashi, H., Miyazaki, T., Yamaguchi, T., Harada, S., Yokoo, T., Uekusa, S., Asakawa, D., Yokoyama, Y., Maruyama, R., Tsujimura, S., Namiki, T., Isoda, R., Enoki, Y., Taguchi, K., & Matsuo, K. (2025). Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae442

Vancouver

Hanai Y, Matsumoto K, Endo A, Hanawa K, Hashi H, Miyazaki T, et al. Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae442

BibTeX
@article{Hanai2025,
  author = {Hanai, Yuki and Matsumoto, Kazuaki and Endo, Aiju and Hanawa, Kazumi and Hashi, Hideki and Miyazaki, Taito and Yamaguchi, Tetsuo and Harada, Sohei and Yokoo, Takuya and Uekusa, Shusuke and Asakawa, Daiki and Yokoyama, Yoshiaki and Maruyama, Riku and Tsujimura, Shun and Namiki, Takaya and Isoda, Ryo and Enoki, Yuki and Taguchi, Kazuaki and Matsuo, Kazuhiro},
  title = {Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae442}
}
Kostenlos starten →